


21. (Amended) A method for inhibiting activity of an alkaline phosphatase, said method comprising contacting the alkaline phosphatase with a compound of formula (I):



where:

A¹ and A² are the same or different aryl groups collectively bearing at least one hydrophilic substituent;

E¹ and E² are the same or different and are O, S, or NR² (where R² is H or a linear or branched C₁-C₂₀ carbon containing group);

M is H or a pharmaceutically acceptable monovalent cation;

R¹ is a linear or branched, saturated or unsaturated, C₁-C₂₀ carbon containing group;

Z is a single bond, a carbonyl, CE³E⁴, or CR³E⁴, where

E³ and E⁴ are the same or different and are OR⁴, SR⁴, and NR⁴₂, where

R³ is a linear or branched C₁-C₂₀ carbon containing group, and

R⁴ is H or a linear or branched C₁-C₂₀ carbon containing group; and

n is 0 or 1,

or a pharmaceutically acceptable salt thereof.

29. (Amended) The method of claim 21 where the compound is 2'-phosphophloretin, 2'-thiophosphophloretin, 2'-aminophosphophloretin, 3-azido-2'-phosphophloretin, or 4-azido-2'-phosphophloretin or a pharmaceutically acceptable salt thereof.

47. (Amended) The method of claim 39 where the compound is 2'-phosphophloretin, 2'-thiophosphophloretin, 2'-aminophosphophloretin, 3-azido-2'-phosphophloretin, or 4-azido-2'-phosphophloretin or a pharmaceutically acceptable salt thereof.

68. (Amended) The method of claim 60 where the a compound is 2'-phosphophloretin, 2'-thiophosphophloretin, 2'-aminophosphophloretin, 3-azido-2'-phosphophloretin, or 4-azido-2'-phosphophloretin or a pharmaceutically acceptable salt thereof.

In accordance with 37 C.F.R. § 1.121(c)(1)(ii), a marked-up version of the claims amended above showing the changes relative to the claims pending immediately prior to the present amendment is attached hereto in an addendum entitled "ADDENDUM TO AMENDMENT DATED JUNE 6, 2003". In this addendum, deletions are indicated by square brackets and insertions are indicated by underlining.

REMARKS

Claims 21-77 are pending in the subject application. Hereinabove, claims 21, 29, 47, and 68 have been amended. Therefore, the claims now under consideration are claims 21-77, as amended. In view of the above amendments and the following remarks, applicant respectfully requests reconsideration of the rejections set forth in the outstanding office action.

As a preliminary matter, applicant notes that the outstanding office action, in the paragraph bridging pages 2 and 3 thereof, states that "[t]his application currently names joint inventors." This is not the case. Only one inventor is named: Brian E. Pearce. Applicant respectfully requests that the PTO ensure that its records are correct in this regard.